Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.70 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 10/20 | 0.60 |
| ▸ | NPC1 | O15118 | 6/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | STAT1 | P42224 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium SCHEMBL209869 | 0.98 | L3MBTL1 (0.68) | L3MBTL1PTK2RAB9ANPC1TDP1 | |
| Hydrochloric Acid SCHEMBL329950 | 0.98 | L3MBTL1 (0.68) | L3MBTL1PTK2RAB9ANPC1TDP1 | |
| SCHEMBL209867 | 0.98 | L3MBTL1 (0.68) | L3MBTL1PTK2RAB9ANPC1TDP1 | |
| Ethyl Chloride SCHEMBL21273828 | 0.92 | PTK2 (0.61) | L3MBTL1PTK2RAB9ANPC1TDP1 | |
| SCHEMBL24654650 | 0.90 | L3MBTL1 (0.78) | L3MBTL1PTK2RAB9ANPC1TDP1 | |
| Lithium Ion SCHEMBL209868 | 0.86 | L3MBTL1 (0.66) | L3MBTL1PTK2RAB9ANPC1TDP1 | |
| SCHEMBL4124368 | 0.85 | L3MBTL1 (0.75) | L3MBTL1PTK2RAB9ANPC1TDP1 | |
| SCHEMBL10015596 | 0.84 | PTK2 (0.74) | L3MBTL1PTK2RAB9ANPC1TDP1 | |
| SCHEMBL2632202 | 0.84 | L3MBTL1 (0.68) | L3MBTL1PTK2RAB9ANPC1TDP1 | |
| Hydrochloric Acid SCHEMBL4953050 | 0.82 | L3MBTL1 (0.66) | L3MBTL1PTK2RAB9ANPC1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024185438-A1 | AZIDE COMPOUND, AMINE COMPOUND, AND METHOD FOR PRODUCING EDOXABAN | 株式会社カネカ | 2024-09-12 | — | — | WO | claimed |
| EP-3752488-B1 | METHOD FOR PREPARING TERT-BUTYL N-((1R,2S,5S)-2-((2-((5-CHLOROPYRIDIN-2-YL)AMINO)-2-OXOACETYL)AMINO)-5-(DIMETHYLCARBAMOYL)CYCLOHEXYL)CARBAMATE | MOEHS IBERICA SL (ES) | 2023-03-08 | — | — | EP | claimed |
| WO-2025075234-A1 | NOVEL METHOD FOR PREPARING EDOXABAN | 주식회사 파마코스텍 | 2025-04-10 | — | — | WO | disclosed |
| WO-2024185438-A1 | AZIDE COMPOUND, AMINE COMPOUND, AND METHOD FOR PRODUCING EDOXABAN | 株式会社カネカ | 2024-09-12 | — | — | WO | disclosed |
| WO-2024009206-A1 | A PROCESS FOR THE PREPARATION OF EDOXABAN AND ITS INTERMEDIATES | AMI LIFESCIENCES PRIVATE LIMITED (IN) | 2024-01-11 | — | — | WO | disclosed |
| WO-2023223346-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF EDOXABAN INTERMEDIATE | MYLAN LABORATORIES LIMITED (IN) | 2023-11-23 | — | — | WO | disclosed |
| EP-3752488-B1 | METHOD FOR PREPARING TERT-BUTYL N-((1R,2S,5S)-2-((2-((5-CHLOROPYRIDIN-2-YL)AMINO)-2-OXOACETYL)AMINO)-5-(DIMETHYLCARBAMOYL)CYCLOHEXYL)CARBAMATE | MOEHS IBERICA SL (ES) | 2023-03-08 | — | — | EP | disclosed |
| EP-3752488-A1 | METHOD FOR PREPARING TERT-BUTYL N-((1R,2S,5S)-2-((2-((5-CHLOROPYRIDIN-2-YL)AMINO)-2-OXOACETYL)AMINO)-5-(DIMETHYLCARBAMOYL)CYCLOHEXYL)CARBAMATE | Moehs Ibérica, S.L. (ES) | 2020-12-23 | — | — | EP | disclosed |
| US-20200352931-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2020-11-12 | — | — | US | disclosed |
| US-20200352931-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2020-11-12 | — | — | US | disclosed |
| EP-3724177-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2020-10-21 | — | — | EP | disclosed |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100093785-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090270446-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-7576135-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7365205-B2 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-04-29 | — | — | US | disclosed |
| US-7342014-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | C1R, C9, C1S | L3MBTL1 91/4885PTK2 3479/4885RAB9A 3871/4885 |
| US-20090270446-A1 | DIAMINE DERIVATIVES | F2, TFPI, F3 | L3MBTL1 4055/4885PTK2 1595/4885RAB9A 2734/4885 |
| US-20200352931-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | L3MBTL1 4472/4885PTK2 4495/4885RAB9A 4766/4885 |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | F2, PLAT, MPL | L3MBTL1 1698/4885PTK2 1038/4885RAB9A 1817/4885 |
| US-20080015215-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | L3MBTL1 385/4885PTK2 3877/4885RAB9A 3294/4885 |
| US-20100093785-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | L3MBTL1 309/4885PTK2 3567/4885RAB9A 3393/4885 |
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | C1R, C9, F2 | L3MBTL1 1605/4885PTK2 3096/4885RAB9A 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.